Oramed Pharmaceuticals Stock Forecast, Price & News

+1.42 (+7.30 %)
(As of 09/16/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume942,383 shs
Average Volume724,343 shs
Market Capitalization$678.57 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Oramed Pharmaceuticals logo

About Oramed Pharmaceuticals

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.96 out of 5 stars

Medical Sector

398th out of 1,352 stocks

Pharmaceutical Preparations Industry

199th out of 665 stocks

Analyst Opinion: 2.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

Is Oramed Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Oramed Pharmaceuticals stock.
View analyst ratings for Oramed Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Oramed Pharmaceuticals?

Wall Street analysts have given Oramed Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Oramed Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a decrease in short interest during the month of August. As of August 13th, there was short interest totaling 1,380,000 shares, a decrease of 27.7% from the July 29th total of 1,910,000 shares. Based on an average daily volume of 758,400 shares, the short-interest ratio is presently 1.8 days. Currently, 4.9% of the shares of the company are short sold.
View Oramed Pharmaceuticals' Short Interest

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 23rd 2021.
View our earnings forecast for Oramed Pharmaceuticals

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its earnings results on Tuesday, July, 13th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03. The biotechnology company earned $0.68 million during the quarter, compared to analyst estimates of $0.70 million. Oramed Pharmaceuticals had a negative net margin of 680.53% and a negative trailing twelve-month return on equity of 40.91%.
View Oramed Pharmaceuticals' earnings history

How has Oramed Pharmaceuticals' stock been impacted by Coronavirus?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ORMP shares have increased by 530.5% and is now trading at $20.87.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ORMP?

4 equities research analysts have issued 12-month price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $20.00 to $30.00. On average, they expect Oramed Pharmaceuticals' stock price to reach $25.00 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:
  • Nadav Kidron, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Joshua Hexter, Chief Operating & Business Officer
  • David Silberman, Chief Financial Officer, Secretary & Treasurer
  • Miriam Kidron, Director & Chief Scientific Officer
  • Michael Rabinowitz, Chief Commercial Officer

Who are some of Oramed Pharmaceuticals' key competitors?

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.90%), State Street Corp (1.08%), Geode Capital Management LLC (0.67%), Northern Trust Corp (0.65%), Millennium Management LLC (0.62%) and Vanguard Group Inc. (0.38%).
View institutional ownership trends for Oramed Pharmaceuticals

Which institutional investors are selling Oramed Pharmaceuticals stock?

ORMP stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Susquehanna International Group LLP, Close Asset Management Ltd, Oppenheimer & Co. Inc., and Citigroup Inc..
View insider buying and selling activity for Oramed Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Oramed Pharmaceuticals stock?

ORMP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Morgan Stanley, and Morgan Stanley.
View insider buying and selling activity for Oramed Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $20.87.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals has a market capitalization of $678.57 million and generates $2.71 million in revenue each year. The biotechnology company earns $-11,510,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Oramed Pharmaceuticals have?

Oramed Pharmaceuticals employs 12 workers across the globe.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is

Where are Oramed Pharmaceuticals' headquarters?

Oramed Pharmaceuticals is headquartered at 1185 AVENUE SUITE 228, NEW YORK NY, 10036.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at (844) 967-2633 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.